{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:44:49Z","timestamp":1759970689486,"version":"build-2065373602"},"reference-count":30,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T00:00:00Z","timestamp":1738195200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background. The Hippo pathway is the most frequently altered signaling in pleural mesothelioma (PM). Epithelioid PM (ePM) is associated with better outcome than non-epithelioid subtypes, but its prognosis can be heterogeneous. Here, we tried to stratify ePM using the expression levels of the Hippo-TEAD network. Methods. Thirty patients with ePM were included in this study. Tumors were stratified using the expression levels of 74 genes belonging to the Hippo-TEAD network and using the non-negative matrix factorization algorithm. Results were validated using ePM cases from the TCGA cohort. Alterations associated with the molecular subgroups were investigated using mutation and copy number alteration data from TCGA. Results. Two groups of ePM (i.e., HP1 and HP2) were identified and validated using TCGA data. HP2 comprises about one-third of tumors. These tumors are frequently high-grade (73% vs. 35%), have higher levels of downstream Hippo effectors (i.e., YAP1, WWTR1 and TEADs), lower levels of VSIR\u2014which encodes for VISTA\u2014and poorer PFS and OS. HP2 tumors commonly harbor homodeletions in Hippo core suppressors (25% vs. 3%), while no specific gene mutation or copy number alterations of Hippo genes was associated with the two groups. Conclusions. ePM can be stratified in prognostic subtypes based on the expression levels of the Hippo-TEAD network. Higher levels of downstream Hippo effectors are associated with poor response to platinum-pemetrexed doublet and worse OS. The stratification of ePM based on the activation of the YAP\/TAZ-TEAD axis is an intriguing approach in the light of the inhibitors of this signaling that are currently under investigation.<\/jats:p>","DOI":"10.3390\/cancers17030469","type":"journal-article","created":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T11:08:23Z","timestamp":1738235303000},"page":"469","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic Stratification of Epithelioid Pleural Mesothelioma Based on the Hippo-TEADs Network"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0212-8249","authenticated-orcid":false,"given":"Anello Marcello","family":"Poma","sequence":"first","affiliation":[{"name":"Department of Surgical, Medical, Molecular Pathology and Critical Area, University of Pisa, 56126 Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rossella","family":"Bruno","sequence":"additional","affiliation":[{"name":"Unit of Pathological Anatomy, University Hospital of Pisa, 56126 Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7752-6866","authenticated-orcid":false,"given":"Iacopo","family":"Petrini","sequence":"additional","affiliation":[{"name":"Department of Translational Research and of New Surgical and Medical Technologies, University of Pisa, 56126 Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8397-6479","authenticated-orcid":false,"given":"Ios\u00e8","family":"Di Stefano","sequence":"additional","affiliation":[{"name":"Department of Surgical, Medical, Molecular Pathology and Critical Area, University of Pisa, 56126 Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Celi","sequence":"additional","affiliation":[{"name":"Department of Surgical, Medical, Molecular Pathology and Critical Area, University of Pisa, 56126 Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4460-5282","authenticated-orcid":false,"given":"Andrea","family":"Sbrana","sequence":"additional","affiliation":[{"name":"Unit of Pneumology, University Hospital of Pisa, 56124 Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabrina","family":"Cappelli","sequence":"additional","affiliation":[{"name":"Unit of Pneumology, University Hospital of Pisa, 56124 Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4325-759X","authenticated-orcid":false,"given":"Antonio","family":"Chella","sequence":"additional","affiliation":[{"name":"Unit of Pneumology, University Hospital of Pisa, 56124 Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1773-8269","authenticated-orcid":false,"given":"Franca","family":"Melfi","sequence":"additional","affiliation":[{"name":"Department of Surgical, Medical, Molecular Pathology and Critical Area, University of Pisa, 56126 Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9909-6820","authenticated-orcid":false,"given":"Marco","family":"Lucchi","sequence":"additional","affiliation":[{"name":"Department of Surgical, Medical, Molecular Pathology and Critical Area, University of Pisa, 56126 Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Greta","family":"Al\u00ec","sequence":"additional","affiliation":[{"name":"Department of Surgical, Medical, Molecular Pathology and Critical Area, University of Pisa, 56126 Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,1,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S2213-2600(24)00111-5","article-title":"Leveraging the Pleural Space for Anticancer Therapies in Pleural Mesothelioma","volume":"12","author":"Blyth","year":"2024","journal-title":"Lancet Respir. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA A Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.jtho.2021.12.014","article-title":"The 2021 WHO Classification of Tumors of the Pleura: Advances Since the 2015 Classification","volume":"17","author":"Sauter","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.annonc.2021.11.005","article-title":"Malignant Pleural Mesothelioma: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up","volume":"33","author":"Popat","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-Line Nivolumab plus Ipilimumab in Unresectable Malignant Pleural Mesothelioma (CheckMate 743): A Multicentre, Randomised, Open-Label, Phase 3 Trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng.3520","article-title":"Comprehensive Genomic Analysis of Malignant Pleural Mesothelioma Identifies Recurrent Mutations, Gene Fusions and Splicing Alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat. Genet."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1038\/s41416-022-01979-0","article-title":"Genomic Landscape of Pleural and Peritoneal Mesothelioma Tumours","volume":"127","author":"Hiltbrunner","year":"2022","journal-title":"Br. J. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e18330","DOI":"10.1111\/jcmm.18330","article-title":"YAP\/TAZ-TEAD Signalling Axis: A New Therapeutic Target in Malignant Pleural Mesothelioma","volume":"28","author":"Papavassiliou","year":"2024","journal-title":"J. Cell. Mol. Medi"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/j.celrep.2018.10.001","article-title":"Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer","volume":"25","author":"Wang","year":"2018","journal-title":"Cell Rep."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Poma, A.M., Torregrossa, L., Bruno, R., Basolo, F., and Fontanini, G. (2018). Hippo Pathway Affects Survival of Cancer Patients: Extensive Analysis of TCGA Data and Review of Literature. Sci. Rep., 8.","DOI":"10.1038\/s41598-018-28928-3"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"4491","DOI":"10.1158\/1538-7445.AM2023-4491","article-title":"Abstract 4491: TY-0584: A Potent, Orally Available Small Molecule YAP\/TEAD Inhibitor, Exhibits Anti-Tumor Effects in Vitro and in Vivo","volume":"83","author":"Liang","year":"2023","journal-title":"Cancer Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.tibs.2022.12.005","article-title":"Therapeutic Targeting of TEAD Transcription Factors in Cancer","volume":"48","author":"Pobbati","year":"2023","journal-title":"Trends Biochem. Sci."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"CT006","DOI":"10.1158\/1538-7445.AM2023-CT006","article-title":"Abstract CT006: First-in-Class, First-in-Human Phase 1 Trial of VT3989, an Inhibitor of Yes-Associated Protein (YAP)\/Transcriptional Enhancer Activator Domain (TEAD), in Patients (Pts) with Advanced Solid Tumors Enriched for Malignant Mesothelioma and Other Tumors with Neurofibromatosis 2 (NF2) Mutations","volume":"83","author":"Yap","year":"2023","journal-title":"Cancer Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"LB319","DOI":"10.1158\/1538-7445.AM2023-LB319","article-title":"Abstract LB319: IAG933, a Selective and Orally Efficacious YAP1\/WWTR1(TAZ)-panTEAD Protein-Protein Interaction Inhibitor with Pre-Clinical Activity in Monotherapy and Combinations","volume":"83","author":"Schmelzle","year":"2023","journal-title":"Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1158\/1538-7445.AM2024-1656","article-title":"Abstract 1656: ISM6331, a Novel and Potent Pan-TEAD Inhibitor, Exhibits Strong Anti-Tumor Activity in Preclinical Models of Hippo Pathway-Dysregulated Cancers","volume":"84","author":"Li","year":"2024","journal-title":"Cancer Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"4964","DOI":"10.1158\/1538-7445.AM2023-4964","article-title":"Abstract 4964: SW-682: A Novel TEAD Inhibitor for the Treatment of Cancers Bearing Mutations in the Hippo Signaling Pathway","volume":"83","author":"Chen","year":"2023","journal-title":"Cancer Res."},{"key":"ref_17","first-page":"1060","article-title":"A Gene-expression-based Test Can Outperform Bap1 and P16 Analyses in the Differential Diagnosis of Pleural Mesothelial Proliferations","volume":"19","author":"Bruno","year":"2019","journal-title":"Oncol. Lett."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1080\/13543784.2019.1638363","article-title":"What Can Independent Research for Mesothelioma Achieve to Treat This Orphan Disease?","volume":"28","author":"Guazzelli","year":"2019","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jtho.2019.08.2506","article-title":"EURACAN\/IASLC Proposals for Updating the Histologic Classification of Pleural Mesothelioma: Towards a More Multidisciplinary Approach","volume":"15","author":"Nicholson","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1200\/JCO.2017.76.6394","article-title":"Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Kindler","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1038\/s41467-019-09307-6","article-title":"Dissecting Heterogeneity in Malignant Pleural Mesothelioma through Histo-Molecular Gradients for Clinical Applications","volume":"10","author":"Blum","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1158\/2159-8290.CD-18-0804","article-title":"Integrative Molecular Characterization of Malignant Pleural Mesothelioma","volume":"8","author":"Hmeljak","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Saddozai, U.A.K., Wang, F., Khattak, S., Akbar, M.U., Badar, M., Khan, N.H., Zhang, L., Zhu, W., Xie, L., and Li, Y. (2022). Define the Two Molecular Subtypes of Epithelioid Malignant Pleural Mesothelioma. Cells, 11.","DOI":"10.3390\/cells11182924"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1093\/carcin\/bgu227","article-title":"Mesothelioma Patients with Germline BAP1 Mutations Have 7-Fold Improved Long-Term Survival","volume":"36","author":"Baumann","year":"2015","journal-title":"Carcinogenesis"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Ganzinelli, M., Guffanti, F., Ianza, A., Sobhani, N., Crovella, S., Zanconati, F., Bottin, C., Confalonieri, M., Fumagalli, S., and Guglielmi, A. (2023). Epithelioid Mesothelioma Patients with Very Long Survival Display Defects in DNA Repair. Cancers, 15.","DOI":"10.3390\/cancers15174309"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/s41392-022-01191-9","article-title":"The Hippo Signalling Pathway and Its Implications in Human Health and Diseases","volume":"7","author":"Fu","year":"2022","journal-title":"Sig. Transduct. Target. Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/s41379-019-0364-z","article-title":"V-Domain Ig-Containing Suppressor of T-Cell Activation (VISTA), a Potentially Targetable Immune Checkpoint Molecule, Is Highly Expressed in Epithelioid Malignant Pleural Mesothelioma","volume":"33","author":"Muller","year":"2020","journal-title":"Mod. Pathol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"He, X.-L., Zhou, Y., Lu, H.-Z., Li, Q.-X., and Wang, Z. (2020). Prognostic Value of VISTA in Solid Tumours: A Systematic Review and Meta-Analysis. Sci. Rep., 10.","DOI":"10.1038\/s41598-020-59608-w"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Arak, H., I\u015f\u0131k, A.F., \u015eanl\u0131, M., Ulu\u015fan, A., Elma, B., and Aytekin, A. (2024). Comparison of Surgical Treatment and Systemic Chemotherapy in Patients with Non-Epithelioid Malignant Pleural Mesothelioma. Asian J. Surg., S101595842402726X.","DOI":"10.1016\/j.asjsur.2024.11.099"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/3\/469\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T10:39:01Z","timestamp":1759919941000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/3\/469"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,30]]},"references-count":30,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["cancers17030469"],"URL":"https:\/\/doi.org\/10.3390\/cancers17030469","relation":{},"ISSN":["2072-6694"],"issn-type":[{"type":"electronic","value":"2072-6694"}],"subject":[],"published":{"date-parts":[[2025,1,30]]}}}